Nucleic Acid Amplification Test for Tuberculosis

Slides:



Advertisements
Similar presentations
Tuberculosis Update Rachel L. Stricof, Epidemiologist
Advertisements

TB Disease and Latent TB Infection
Nick Curry, MD, MPH Infectious Diseases Prevention Section
Molecular testing for detection of Mycobacterium tuberculosis San Francisco Department of Public Health Laboratory.
` COMPARATIVE ACCURACY OF CARTRIDGE BASED NUCLEIC ACID AMPLIFICATION TEST AND SPUTUM MICROSCOPY FOR DIAGNOSIS OF PULMONARY TUBERCULOSIS IN HIV POSITIVE.
A typical day in the TB clinic You see the following patients in the TB clinic. All have normal CXRs: 1. A 35 year old man from Hartford with a 16 mm positive.
Mortality Among a Tuberculosis Outbreak Los Angeles County, 2007–2013 Brian Baker, MD Amit Chitnis, MD MPH Leslie Henry, BSN RN PHN 48th CTCA Educational.
World Health Organization TB Case Definitions
MDCH STATE LABORATORY TUBERCULOSIS TESTING Specimens/Tests/Reports
Nucleic Acid Amplification Test for Tuberculosis
Introduction to Tuberculosis
Why do we test? 1.We want to prevent an outbreak of Tuberculosis in our campus community 2.We want to find those that are affected and get them treated.
Diagnosis of TB.
* TB is caused by a bacterium called Mycobacterium Tuberculosis. The bacteria usually attacks the lungs, but TB bacteria can attack any part of the.
Culture Conversion and Self- Administered Therapy in Privately Managed Tuberculosis Patients Melissa Ehman MPH, Jennifer Flood MD MPH, Pennan Barry MD.
Colorado Department of Public Health and Environment Tuberculosis Prevention and Control Program.
Tuberculosis Research of INA-RESPOND on Drug-resistant
Tuberculosis Egan’s Chapter 22. Mosby items and derived items © 2009 by Mosby, Inc., an affiliate of Elsevier Inc. 2 Tuberculosis (TB) The incidence of.
CLINICAL DIAGNOSTIC TB LABORATORY Alexander Sloutsky, Director University of Massachusetts Supranational Reference TB Laboratory Boston, MA.
V IRGINIA C OHORT D ATA – 5 YEAR TRENDS AFTER 4 YEARS OF LOCAL COHORT REVIEW Virginia achievement on National TB Indicators for the past 5 years – where.
Introduction to Tuberculosis Genotyping National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of Tuberculosis Elimination.
ITT TECHNICAL INSTITUTE SCHOOL OF HEALTH SCIENCES Nursing Department ITT TECHNICAL INSTITUTE SCHOOL OF HEALTH SCIENCES Nursing Department Mandatory Tuberculosis.
Beyond Sputum Cups and Four Drugs The Responsibility of the Practicing Clinician in the Community Control of Tuberculosis V. R. Koppaka, MD, PhD Division.
CDC Guidelines for Use of QuantiFERON ® -TB Gold Test Philip LoBue, MD Centers for Disease Control and Prevention Division of Tuberculosis Elimination.
Module 2 TB Disease Transmission & Prevention. Pulmonary Tuberculosis Extra -Pulmonary TB an infectious disease caused by a microorganism called Mycobacterium.
NAAT Is it Time for a New Option in California?. Background CDC 2009 guidelines recommend NAAT for each patient with suspected TB for whom the test result.
Update in the Diagnosis of Tuberculosis in Children Ana M. Alvarez, MD, FPIDS Associate Professor Division of Pediatric Infectious Diseases and Immunology.
L.A. County Public Health Partnering with the Private Community to Control TB Myrna Mesrobian, MD, MPH.
TB Transmission What is TB? aTB is a disease caused by infection with a bacteria called Mycobacterium tuberculosis.
TB Prevention and Control in Correctional and Detention Facilities Mark Lobato, MD Division of TB Elimination Centers for Disease Control and Prevention.
Diagnosis of pulmonary tuberculosis
What’s New With Your Maryland State Lab. Richard Oatis Supervisor, Mycobacteriology State of Maryland Department of Health and Mental Hygiene Labs Administration.
Roundtable. Detection and treatment of TB Andrew Black.
INSTITUTO DE INFECTOLOGIA EMÍLIO RIBAS Identification of Mycobacterium tuberculosis complex in clinical specimens of HIV-infected patients at Instituto.
EPIDEMIOLOGY OF PULMONARY TUBERCULOSIS. LEARNIN G OBJECTIVES State the diagnostic criteria of pulmonary tuberculosis Describe trend & state reasons for.
TB – LABORATORY INVESTIGATIONS by Dr. Zubaidah Abdul Wahab Datin Dr. Ganeswrie Raj 1.
Tuberculosis in children
Screening International Adoptees
New WHO algorithm to prevent TB deaths in seriously ill patients with HIV Yohhei Hamada TB/HIV and Community Engagement.
Management of the Newborn When Maternal TB Suspected
CASES OF PLEURAL EFFUSION (n=56)
Whole-Genome Sequencing; It’s Not Just For Epis
Infection Control Q and A APIC Greater NY Chapter 13 May 17, 2017 Beth Nivin BA MPH NYC DOHMH Communicable Disease Program
Infant born with mother Tuberculosis
This is an archived document.
Tuberculosis in children in Uzbekistan: Don’t forget drug-resistant TB Junia Cajazeiro, Atadjan Khamraev, Philip Du Cros, Tleubergen Abdrasuliev, Joan.
The Respiratory System
This is an archived document.
Laboratory ‘Network’ Update New York State Department of Health
Epidemiology of pulmonary tuberculosis
How do we delay disease progress once it has started?
CDC Guidelines for Use of QuantiFERON®-TB Gold Test
Presentation 10 Analysing results and defining cases
بسم الله الرحمن الرحيم.
APIC Greater NY Chapter 13 Q&A Session
Further explorations of surveillance data: case detection (all cases vs. bacteriologically confirmed, All strategies) Good afternoon. I will give a brief.
Introduction To Medical Technology
Tuberculosis in children BY MBBSPPT.COM
GENERAL PATHOLOGY Diagnostic Services in Health Care that apply to the various diseases The role of diagnostics in Healthcare Quality procedures.
M.H. Wilcox  Clinical Microbiology and Infection 
DR-TB Case-finding and Referral Procedures
Goal Objectives Expected Outcomes
Deciphering TB Lab Reports
Using Whole Genome Sequencing Analysis in California
Tuberculosis Control Program
A Good Walk Spoiled.
Interview Timeframes Conduct a minimum of 2 interviews: 1st interview
Laura Lane, Epidemiologist
Uses of Genotyping.
Presentation transcript:

Nucleic Acid Amplification Test for Tuberculosis Heidi Behm, RN, MPH Acting TB Controller HIV/STD/TB Program Oregon, Department of Health Services

What is this test? Nucleic Acid Amplification Test (NAAT) identifies genetic material unique to MTB Several NAA test have been FDA approved 1995-Amplified Mycobacterium tuberculosis Direct Test (MTD, Gen-Probe, San Diego, California) was FDA approved in for AFB smear-positive respiratory specimens 1999-An enhanced test (MTD-2) was approved for AFB smear-negative respiratory specimens. Oregon State Public Health Lab (OSPHL) will utilize Gen Probe MTD-2 NAAT is also referred to as Polymerase Chain Reaction (PCR) test.

Why is NAAT so great? TB genetic material can be detected using NAAT within 3-5 hours while cultures take weeks! Find out faster if smear+ is TB vs. NTM (save time and money on drugs, contact investigation, etc) Earlier diagnosis for smear- (less delayed diagnosis and TB transmission, decrease the inappropriate use of fluoroquinolones) It’s easy (no extra sputum needed)! It’s free for LHDs!

How will this work for LHDs? Collect sputum to rule out TB and send to lab as usual OSPHL will test the first sputum with NAAT If the first sputum is smear-/NAAT -, but a subsequent sputum is smear+ that specimen should also get tested. Others tested by special request only If you do not want sputum tested, indicate on lab slip

How do private providers order NAAT? Processed sediments may be sent to OSPHL directly from the lab or hospital There will be a charge of $40.00 for testing The provider should contact OSPHL at 503-693-4100 or see OSPHL web site for further instruction.

When should NAAT not be used? Do not use if patient has taken TB medications in the past 12 months (not a test of cure, not for previously treated B waivers) Can detect nucleic acids from dead and live organisms, so may remain positive long after treatment is completed and the culture is negative Do not use if patient has taken TB medications for more than 7 days Do not use if low suspicion of TB (example, B waiver). Positive predictive value of the NAA test is <50% positive predictive valueis the proportion of patients with positive test results who are correctly diagnosed. It is the most important measure of a diagnostic method as it reflects the probability that a positive test reflects the underlying condition being tested for

What is NAAT MTD-2 FDA approved for? Smear+ sputum specimens Smear- sputum specimens Patients who haven’t received TB treatment Patients who are highly suspected to have TB Isn’t approved for non-respiratory specimens, but there may be clinical utility in using test Further research needed on using for children who cannot produce sputum (gastric aspirates)

How good is this test? Respiratory smear+ specimens from untreated patients with high suspicion for TB. Sensitivity=95%, Specificity=98% Respiratory smear- specimens from untreated patients with high suspicion for TB. Sensitivity=66%, Specificity=98%

How good is NAAT continued… Good test for smear+ Sensitivity for smear- is low (66%) A test with high sensitivity catches all people with a disease. If test has low sensitivity, may believe patient does not have disease when they do (a false negative) MTD-2 detects only 50%--80% of AFB smear-negative, culture-positive pulmonary TB cases

Interpretation of Results Not a perfect test. Does not replace culture results which are the “gold standard”. Interpret within the context of the patient’s symptoms, chest x-ray, smear and culture

Smear+, NAAT+ Presume active TB disease Start contact investigation Start TB medication Keep in isolation until cleared Confirm by culture result

Smear+, NAAT- Suspect nontuberculous mycobacterium (NTM). Does not rule out TB Consider delaying treatment, contact investigation and removing from isolation. But…if highly suspected of TB or lives in congregate setting or with high risk individuals request a second NAAT. Confirm findings with culture result

Smear-, NAAT+ Likely has active TB disease Consider submitting another specimen for NAAT to verify Presumed to have TB if two or more specimens are NAAT positive Use clinical judgment to determine whether to start treatment, start contact investigation and place on isolation. Confirm by culture result

Smear-, NAAT- For smear- specimens, sensitivity is low Diagnosis of TB cannot be excluded Rely on clinical judgment Requesting a second NAAT may be helpful Contact investigation may be delayed and patient considered non-infectious if sputum smear- x 2 and all NAAT results are negative. Confirm by culture result

Inhibited NAAT Amplification was inhibited due to a naturally occurring inhibitor in the specimen or processing reagent (example: blood). Can result in a false negative Test for inhibitors will be automatically run by lab on all smear+, NAAT- specimens If present, lab will contact you for additional specimen to test

Conclusion

Conclusion NAAT will provide LHDs with additional information to base decisions upon LHDs will not need to do anything different when collecting sputum to rule out TB Do not use NAAT if the patient has been on TB meds. for more than 7 days or was treated within last year The TB Program is available to assist with interpretation of results!

Resources State summary: http://www.oregon.gov/DHS/ph/tb/tools/NAATguide.pdf OSPHL: http://oregon.gov/DHS/ph/phl/docs/guide.pdf CDC: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5801a3.htm?s_cid=mm5801a3_e